Pfenex Inc.
Pseudomonas fluorescens-based microbial expression platform for recombinant protein manufacturing
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Founded
- 2009
- Latest Form D
- $24M, Dec 2009
- Total capital
- $28.1M
- Federal grants
- $4.1M
- 3 awards · 2012
- 3.0× sector median 1 award
- Private capital raised
- $24M
- 1 Form D · last Dec 2009
- 203 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 13
- 25 pending · first 2014
- Rank in peer group#21 of 342
Capital timeline
Latest events
- Federal grantHealth and Human S · N01 · Technologies to Advance Next Generation Anthrax Vaccines$851K
- Federal grantHealth and Human S · N01 · Technologies to Advance Next Generation Anthrax Vaccines$1M
- Federal grantHealth and Human S · N01 · Technologies to Advance Next Generation Anthrax Vaccines$2.2M
- Private capital raisedForm D · SEC · 1st filing$24M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#21 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Albert C. HansenDirectorNamed in SEC Form D filings
- Bertrand C. LiangExecutive Officer, DirectorNamed in SEC Form D filings
- Charles H. SquiresExecutive OfficerNamed in SEC Form D filings
- Dennis C. MerensDirectorNamed in SEC Form D filings
- Henry C. TalbotExecutive OfficerNamed in SEC Form D filings
- James C. GaleDirectorNamed in SEC Form D filings
What it has protected
USPTO · 13 granted of 38- PendingMethods Of Purifying Charge-shielded Fusion ProteinsUSPTOApplication 17559978
- GrantedMethod For Production Of Recombinant Erwinia AsparaginaseUSPTOUS 11,377,661
- GrantedMethod For Production Of Recombinant E. Coli AsparaginaseUSPTOUS 11,046,964
Show all 38 patent records
- Methods Of Purifying Charge-shielded Fusion ProteinsJul 21, 2022 · Application 17559978Pending
- Method For Production Of Recombinant Erwinia AsparaginaseJul 5, 2022 · US 11,377,661Granted
- Method For Production Of Recombinant E. Coli AsparaginaseJun 29, 2021 · US 11,046,964Granted
- Fusion Partners For Peptide ProductionApr 20, 2021 · US 10,981,968Granted
- Method For Production Of Recombinant Erwinia AsparaginaseSep 29, 2020 · US 10,787,671Granted
- Method For Rapidly Screening Microbial Hosts To Identify Certain Strains With Improved Yield And/or Quality In The Expression Of Heterologous ProteinsJun 23, 2020 · US 10,689,640Granted
- Method For Production Of Recombinant E. Coli AsparaginaseMay 26, 2020 · US 10,662,433Granted
- Bacterial Leader Sequences For Periplasmic Protein ExpressionMay 2, 2019 · Application 16163421Pending
- Fusion Partners For Peptide ProductionNov 6, 2018 · US 10,118,956Granted
- Expression of Mammalian Proteins in Pseudomonas FluorescensOct 11, 2018 · Application 16014348Pending
- Expression of Mammalian Proteins in Pseudomonas FluorescensAug 7, 2018 · US 10,041,102Granted
- Process For Purifying Recombinant Plasmodium Falciparum Circumsporozoite ProteinDec 26, 2017 · US 9,849,177Granted
- Method For Producing Soluble Recombinant Interferon Protein Without DenaturingApr 4, 2017 · US 9,611,499Granted
- High Level Expression Of Recombinant Toxin ProteinsDec 17, 2015 · Application 14531833Pending
- Process For Purifying Recombinant Plasmodium Falciparum Circumsporozoite ProteinOct 27, 2015 · US 9,169,304Granted
- Process For Improved Protein Expression By Strain EngineeringAug 18, 2015 · US 9,109,229Granted
- High Level Expression Of Recombinant Toxin ProteinsDec 9, 2014 · US 8,906,636Granted
- Method For Producing Soluble Recombinant Interferon Protein Without DenaturingApplication PCTUS2011026921Pending
- Production Of Recombinant Proteins Utilizing Non-antibiotic Selection Methods And The Incorporation Of Non-natural Amino Acids ThereinApplication PCTUS2010034201Pending
- High Level Expression Of Recombinant CRM197Application PCTUS2010030573Pending
- Methods For Expression Of Fusion-free Bovine Ultralong CDR3 ScaffoldApplication 63529931Pending
- Translation Initiation Region Sequences For The Optimal Expression Of Heterologous ProteinsApplication PCTUS2008072070Pending
- Methods For Expression Of Fusion-free Bovine Ultralong CDR3 ScaffoldApplication 63430288Pending
- Methods Of Purifying Charge-shielded Fusion ProteinsApplication PCTUS2021073076Pending
- Bacterial Hosts For Recombinant Protein ExpressionApplication 63209239Pending
- Anthrax VaccineApplication 63209284Pending
- Methods Of Purifying Charge-shielded Fusion ProteinsApplication 63130295Pending
- Method For Production Of Recombinant E. Coli AsparaginaseApplication PCTUS2018056375Pending
- Method For Production Of Recombinant Erwinia AsparaginaseApplication PCTUS2018056374Pending
- Bacterial Leader Sequences For Periplasmic Protein ExpressionApplication PCTUS2018056376Pending
- Method For Production Of Recombinant E. Coli AsparaginaseApplication 62578302Pending
- Bacterial Leader Sequences For Periplasmic Protein ExpressionApplication 62578304Pending
- Method For Production Of Recombinant Erwinia AsparaginaseApplication 62578305Pending
- Fusion Partners For Peptide ProductionApplication PCTUS2015063027Pending
- Fusion Partners For Peptide ProductionApplication 62086119Pending
- Process For Purifying Recombinant Plasmodium Falciparum Circumsporozoite ProteinApplication PCTUS2013037656Pending
- Methods For G-csf Production In A Pseudomonas Host CellApplication PCTUS2011030593Pending
- High Level Expression Of Recombinant Toxin ProteinsApplication PCTUS2011030227Pending
Related companies, and why
- Trait Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- Core Quantum Technologies, Inc.Similar federal contract value in Biotech · null in contracts
- GENVAX TECHNOLOGIES INCSimilar federal contract value in Biotech · null in contracts
- Mesentech Inc.Similar federal contract value in Biotech · null in contracts
- Aer TherapeuticsSimilar federal contract value in Biotech · null in contracts
- GRANATA BIO CorpSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .